Case report: Focal segmental glomerulosclerosis and nephrotic syndrome following treatment with pamidronate for calcitriol toxicity

ObjectiveThis study aimed to describe a case of glomerulosclerosis resulting in nephrotic syndrome following the administration of pamidronate disodium to treat clinical calcitriol toxicity in a dog.Case summaryA 12-week-old intact male Labrador Retriever weighing 11.8 kg presented with lethargy and...

Full description

Bibliographic Details
Main Authors: Katherine Ann Dawson, April Blong, Rebecca Walton
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Veterinary Science
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fvets.2022.956153/full
_version_ 1818085186211938304
author Katherine Ann Dawson
April Blong
Rebecca Walton
author_facet Katherine Ann Dawson
April Blong
Rebecca Walton
author_sort Katherine Ann Dawson
collection DOAJ
description ObjectiveThis study aimed to describe a case of glomerulosclerosis resulting in nephrotic syndrome following the administration of pamidronate disodium to treat clinical calcitriol toxicity in a dog.Case summaryA 12-week-old intact male Labrador Retriever weighing 11.8 kg presented with lethargy and vomiting for 20 h after ingesting a 100 g tube of topical antipsoriatic cream (3 mcg/g of calcitriol; Vectical Ointment™, Galderma, Lausanne, Switzerland). Severe hypercalcemia was present on the day of the presentation. Hypercalcemia treatments such as saline diuresis, furosemide (Salix®, furosemide, Merck Animal Health, Kenilworth, NJ), and dexamethasone sodium phosphate (Dexamethasone SP, Mylan, Canonsburg, PA) were initiated. The dog was also administered a single dose of pamidronate disodium (Pamidronate disodium, Mylan, Canonsburg, PA) on the day of presentation. Initially, the patient's clinical signs improved, and the hypercalcemia resolved. Exactly 130 h post-pamidronate disodium (Dexamethasone SP, Mylan, Canonsburg, PA) administration, the patient developed biochemical abnormalities and severe edema, consistent with nephrotic syndrome, and was euthanized. Necropsy results revealed evidence of focal segmental glomerulosclerosis (FSGS).Unique informationPamidronate disodium, commonly used for the treatment of hypercalcemia, may have resulted in glomerulosclerosis and nephrotic syndrome in a dog with calcitriol toxicity. This complication should be taken into consideration when monitoring patients treated with pamidronate disodium for hypercalcemia.
first_indexed 2024-12-10T20:05:47Z
format Article
id doaj.art-117a2b77c5664fd784c5fc7469c595b6
institution Directory Open Access Journal
issn 2297-1769
language English
last_indexed 2024-12-10T20:05:47Z
publishDate 2022-08-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Veterinary Science
spelling doaj.art-117a2b77c5664fd784c5fc7469c595b62022-12-22T01:35:24ZengFrontiers Media S.A.Frontiers in Veterinary Science2297-17692022-08-01910.3389/fvets.2022.956153956153Case report: Focal segmental glomerulosclerosis and nephrotic syndrome following treatment with pamidronate for calcitriol toxicityKatherine Ann DawsonApril BlongRebecca WaltonObjectiveThis study aimed to describe a case of glomerulosclerosis resulting in nephrotic syndrome following the administration of pamidronate disodium to treat clinical calcitriol toxicity in a dog.Case summaryA 12-week-old intact male Labrador Retriever weighing 11.8 kg presented with lethargy and vomiting for 20 h after ingesting a 100 g tube of topical antipsoriatic cream (3 mcg/g of calcitriol; Vectical Ointment™, Galderma, Lausanne, Switzerland). Severe hypercalcemia was present on the day of the presentation. Hypercalcemia treatments such as saline diuresis, furosemide (Salix®, furosemide, Merck Animal Health, Kenilworth, NJ), and dexamethasone sodium phosphate (Dexamethasone SP, Mylan, Canonsburg, PA) were initiated. The dog was also administered a single dose of pamidronate disodium (Pamidronate disodium, Mylan, Canonsburg, PA) on the day of presentation. Initially, the patient's clinical signs improved, and the hypercalcemia resolved. Exactly 130 h post-pamidronate disodium (Dexamethasone SP, Mylan, Canonsburg, PA) administration, the patient developed biochemical abnormalities and severe edema, consistent with nephrotic syndrome, and was euthanized. Necropsy results revealed evidence of focal segmental glomerulosclerosis (FSGS).Unique informationPamidronate disodium, commonly used for the treatment of hypercalcemia, may have resulted in glomerulosclerosis and nephrotic syndrome in a dog with calcitriol toxicity. This complication should be taken into consideration when monitoring patients treated with pamidronate disodium for hypercalcemia.https://www.frontiersin.org/articles/10.3389/fvets.2022.956153/fullhypercalcemiapamidronateprotein losing nephropathycalcitriol (125(OH) 2D 3)toxicity
spellingShingle Katherine Ann Dawson
April Blong
Rebecca Walton
Case report: Focal segmental glomerulosclerosis and nephrotic syndrome following treatment with pamidronate for calcitriol toxicity
Frontiers in Veterinary Science
hypercalcemia
pamidronate
protein losing nephropathy
calcitriol (1
25(OH) 2D 3)
toxicity
title Case report: Focal segmental glomerulosclerosis and nephrotic syndrome following treatment with pamidronate for calcitriol toxicity
title_full Case report: Focal segmental glomerulosclerosis and nephrotic syndrome following treatment with pamidronate for calcitriol toxicity
title_fullStr Case report: Focal segmental glomerulosclerosis and nephrotic syndrome following treatment with pamidronate for calcitriol toxicity
title_full_unstemmed Case report: Focal segmental glomerulosclerosis and nephrotic syndrome following treatment with pamidronate for calcitriol toxicity
title_short Case report: Focal segmental glomerulosclerosis and nephrotic syndrome following treatment with pamidronate for calcitriol toxicity
title_sort case report focal segmental glomerulosclerosis and nephrotic syndrome following treatment with pamidronate for calcitriol toxicity
topic hypercalcemia
pamidronate
protein losing nephropathy
calcitriol (1
25(OH) 2D 3)
toxicity
url https://www.frontiersin.org/articles/10.3389/fvets.2022.956153/full
work_keys_str_mv AT katherineanndawson casereportfocalsegmentalglomerulosclerosisandnephroticsyndromefollowingtreatmentwithpamidronateforcalcitrioltoxicity
AT aprilblong casereportfocalsegmentalglomerulosclerosisandnephroticsyndromefollowingtreatmentwithpamidronateforcalcitrioltoxicity
AT rebeccawalton casereportfocalsegmentalglomerulosclerosisandnephroticsyndromefollowingtreatmentwithpamidronateforcalcitrioltoxicity